Ray Chen is an influential entrepreneur with more than 30 years of experience in the information technology industry. He was the Executive Vice President of Kinpo Electronics and was appointed President and CEO of Compal Electronics in 1989. In 2018, he became the Vice Chairman and Group CSO.

During his tenure as President and CEO of Compal, Mr. Chen established and led many affiliates and subsidiaries to fulfill Compal’s vertical integration strategy. Expanding from traditional computing to the fields of communications, smart devices, and top-notch networking products, Compal has become one of the world’s largest NB PC manufacturers and a global leader in design and manufacturing, providing products ranging from computing, communication, connected devices to cloud servers. Mr. Chen is the recipient of a great number of awards including "The Best CEO" in Taiwan by Institutional Investors in 2004 and the “International Entrepreneur” title in the E&Y Entrepreneur of The Year 2010 Award, as he guided Compal to becoming a Fortune 500 company and one of Taiwan’s Top 5 technology manufacturers.

With the mission of giving back to society, Mr. Chen has been actively involved in biomedical industries in recent years, with more than 10 biomedical corporations established under Mr. Chen’s guidance. HippoScreen Neurotech Corp. specializes in AI brain diagnostic technology; SHENONA, Inc. is developing Internet of Things (IoT) products for elderly and diabetes patients; General Life Biotechnology Co., Ltd. created a 3-in-1 chip for glucose, total cholesterol, and uric acid detection; Unicore Biomedical Co., Ltd. focuses on medical care and applications of imaging diagnostics on pets. For advances in cell therapy, RayPal Biomedical Co., Ltd. was established. With GTP facility and proprietary know-how, Raypal provides cell therapies and regenerative medicine for various indications. A recent collaboration between Raypal and Kaohsiung Medical University Chung-Ho Memorial Hospital established the foundation of cellular therapy in southern Taiwan. In 2020, ARCE Therapeutics, Inc. was formed to develop novel immune cellular gene therapies for cancer patients.

Ray Chen holds a Bachelor's degree in Electrical Engineering and an Honorary Doctorate in Engineering from National Cheng Kung University, Taiwan.